Paul L. Swiecicki
Experienced in Lymphofollicular Hyperplasia

Dr. Paul L. Swiecicki

Oncology | Hematology
Regents Of The University Of Michigan
1500 E Medical Ctr Dr, 
Ann Arbor, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Lymphofollicular Hyperplasia
Regents Of The University Of Michigan
1500 E Medical Ctr Dr, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Swiecicki is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Swiecicki is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Oral Squamous Cell Carcinoma. Dr. Swiecicki is currently accepting new patients.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lymphofollicular Hyperplasia.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Of Michigan Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Sanford Health
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr Dr, Ann Arbor, MI 48109
Other Locations
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr, Suite 0331, Ann Arbor, MI 48109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, IRX-2
Study Phase: Phase 1
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: APG-115, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Enrollment Status: Terminated
Publish Date: December 06, 2022
Intervention Type: Biological
Study Drug: RPTR-168
Study Phase: Phase 1
Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.
Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.
Enrollment Status: Terminated
Publish Date: December 06, 2022
Intervention Type: Diagnostic test
Phase II Expansion Trial Evaluating Axitinib in Patients With Unresectable Recurrent, or Metastatic Head and Neck Cancer Utilizing Choi Response Criteria Phase
Phase II Expansion Trial Evaluating Axitinib in Patients With Unresectable Recurrent, or Metastatic Head and Neck Cancer Utilizing Choi Response Criteria Phase
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Drug: Axitinib
Study Phase: Phase 2
A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

90 Total Publications

CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma.
CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma.
Journal: Head & neck
Published: August 07, 2025
Similar Doctors
Parvez Khan
Distinguished in Lymphofollicular Hyperplasia
Dr. Parvez Khan
Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Parvez Khan
Oncology

Hematology/Oncology Center

6255 Inkster Road, Suite 307, 
Garden City, MI 
 (21.5 miles away)
734-743-8790
Experience:
50+ years
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Parvez Khan is an Oncologist in Garden City, Michigan. Dr. Khan has been practicing medicine for over 50 years and is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Agranulocytosis, Chronic Familial Neutropenia, Idiopathic Neutropenia, and Bone Marrow Aspiration. Dr. Khan is currently accepting new patients.

Advanced in Lymphofollicular Hyperplasia
Dr. Vatsala Katragadda
Hematology | Oncology
Advanced in Lymphofollicular Hyperplasia
Dr. Vatsala Katragadda
Hematology | Oncology

Mclaren Flint

4100 Beecher Rd, Suite B, 
Flint, MI 
 (50.4 miles away)
810-235-8568
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vatsala Katragadda is a Hematologist and an Oncologist in Flint, Michigan. Dr. Katragadda is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphofollicular Hyperplasia. Dr. Katragadda is currently accepting new patients.

Mohammad M. Chisti
Advanced in Lymphofollicular Hyperplasia
Dr. Mohammad M. Chisti
Hematology | Oncology
Advanced in Lymphofollicular Hyperplasia
Dr. Mohammad M. Chisti
Hematology | Oncology

Corewell Health Beaumont Troy Hospital Hematology & Oncology - 44199 Dequindre Rd

44199 Dequindre Road, Suite G-10, 
Troy, MI 
 (39.8 miles away)
248-964-6111
Experience:
21+ years
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Chisti is a Hematologist and an Oncologist in Troy, Michigan. Dr. Chisti has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Follicular Lymphoma, Chronic Myelogenous Leukemia (CML), Anemia, Bone Marrow Aspiration, and Gastrostomy. Dr. Chisti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Swiecicki's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile